What is the dosage of Mounjaro (tirzepatide)?

From the Guidelines

Mounjaro (tirzepatide) should be administered at a maximum approved daily dose of 15 mg once weekly. The dosage of Mounjaro (tirzepatide) is clearly outlined in the provided evidence from the 2023 study published in Diabetes Care 1. According to the study, the maximum approved daily dose of Mounjaro (tirzepatide) is 15 mg, which is administered once weekly.

Key Points to Consider

• The initial dose and titration schedule for Mounjaro (tirzepatide) are crucial for minimizing gastrointestinal side effects and maximizing efficacy.
• The dose can be gradually increased in 2.5 mg increments every 4 weeks up to a maximum of 15 mg once weekly, based on individual response and tolerability.
• Common side effects of Mounjaro (tirzepatide) include nausea, diarrhea, decreased appetite, vomiting, and constipation, which often improve over time.
• Patients should inject Mounjaro (tirzepatide) on the same day each week, but can change the day if needed as long as the last dose was administered at least 3 days (72 hours) prior.

Administration and Storage

• Mounjaro (tirzepatide) should be stored in the refrigerator until use and can be kept at room temperature for up to 24 hours.
• The medication works by activating both GLP-1 and GIP receptors, which helps improve insulin secretion, reduce glucagon levels, slow gastric emptying, and reduce appetite, making it effective for both blood sugar control and weight management, as supported by the study 1.

From the FDA Drug Label

2 DOSAGE AND ADMINISTRATION

2.1 Dosage The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)]. The 2. 5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2. 5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.

The dosage of Mounjaro (tirzepatide) is as follows:

• Starting dosage: 2.5 mg injected subcutaneously once weekly
• Dosage escalation: increase to 5 mg after 4 weeks, and then in 2.5 mg increments every 4 weeks as needed
• Maximum dosage: 15 mg injected subcutaneously once weekly 2

From the Research

Dosage of Mounjaro (Tirzepatide)

• The dosage of Mounjaro (tirzepatide) is administered once-weekly via subcutaneous injection, with doses of 5 mg, 10 mg, and 15 mg studied in clinical trials 3, 4, 5.
• In the SURPASS clinical trials, tirzepatide was initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved 4.
• The most common doses used in clinical trials were 5 mg, 10 mg, and 15 mg per week, with significant improvements in glycemic control and weight loss observed at all doses 3, 4, 5, 6.
• The efficacy and safety of tirzepatide have been demonstrated in several clinical trials, including the SURPASS-1 through SURPASS-5 trials, which showed significant reductions in glycated hemoglobin and body weight, as well as improvements in other parameters associated with cardiometabolic risk 3, 4, 5, 6.

Administration and Tolerability

• Tirzepatide is administered via subcutaneous injection, and is generally well-tolerated, with a safety profile similar to that of GLP-1 receptor agonists 7, 3, 5, 6.
• The most common adverse events associated with tirzepatide are gastrointestinal in nature, including nausea, diarrhea, and vomiting 7, 3, 4, 5.